Psoriatic Arthritis

Tumor necrosis factor-α antagonists used to treat autoimmune diseases such as rheumatoid arthritis may pose less risk of serious infection than previously thought, a new study suggests.

The FDA declined to approve Simponi (golimumab) for use in limiting the advance of structural damage in patients with moderate to severe rheumatoid arthritis.

NICE has issued final guidance recommending golimumab for the treatment of psoriatic arthritis.

New AAD guidelines outline the recommended approach to treating patients with mild to severe cases of psoriasis.

Tim Gunn, Pfizer, and Amgen teamed up to offer style and fashion advice for patients who have been diagnosed with psoriasis.

Researchers discover four DNA

A survey reveals that rheumatologists and dermatologists expect to increase their use of Centocor Ortho Biotech's Simponi .

A second biologic option is now available for patients in New Zealand with forms of arthritis.